Noninvasive Stereotactic Body Radiotherapy for Treating Ventricular Tachycardia in Patients with Structural Heart Disease

What this Trial Is About

Ventricular tachycardia VT causes over 350,000 sudden deaths annually in the US, often due to electrical disruptions in heart tissue scars. This study evaluates a new non-invasive treatment option called stereotactic body radiotherapy SBRT for patients with VT who have not responded to or cannot tolerate standard treatments such as implantable defibrillators, drug therapy, or catheter ablation. The goal is to explore if SBRT can reduce dangerous heart rhythm events by targeting the heart scar tissue causing VT. The study is a single-center, single-arm prospective cohort involving 12 patients who will receive SBRT after detailed imaging and mapping of their heart. Imaging techniques like 4D cardiac CT and cardiac MRI for some patients will be used to plan the radiation treatment precisely. The SBRT procedure is administered using a linear accelerator and lasts about 30 minutes. After treatment, patients will be followed up at intervals to monitor outcomes and heart device data for up to two years. Participants will undergo initial imaging and have their medical history and prior treatments reviewed to create a personalized radiation plan. Follow-ups occur at 6 and 12 weeks, 7.5 months, and then every 6 months to assess the treatments success and review heart device records. Researchers will measure the number of ventricular arrhythmia events before and after treatment and monitor for any complications such as heart failure or other injuries. The study aims to provide detailed safety and effectiveness data over a follow-up period ranging from 7.5 months to two years.

Cohort Study - SBRT for VT Radioablation